Best Alzheimer Disease Treatment Doctors in India

What Patients with Alzheimer Disease Worry About Most

Alzheimer disease changes families, not just patients. The big worries are how fast the decline will be, whether the new amyloid-targeting drugs will work for their stage, how to keep the person safe at home, and how to plan finances and care before capacity is lost. Caregivers also need support. Honest staging, a structured care plan, and early use of cholinesterase inhibitors or memantine slow function loss in most patients.

How Alzheimer Disease Is Diagnosed

Diagnosis combines clinical assessment with biomarkers. The neurologist does a cognitive screen (Mini-Mental State Examination, Montreal Cognitive Assessment, Addenbrooke Cognitive Examination). Magnetic resonance imaging of the brain looks for hippocampal atrophy and rules out stroke, tumour, or normal pressure hydrocephalus. Blood tests cover vitamin B12, thyroid function, and HIV or syphilis. Cerebrospinal fluid amyloid-beta forty-two, total tau, and phosphorylated tau, or amyloid positron emission tomography, confirm Alzheimer pathology when needed. Plasma phosphorylated tau two-one-seven is the newest blood biomarker being rolled out.

Treatment Options for Alzheimer Disease in India

Mild to moderate disease: cholinesterase inhibitors (donepezil, rivastigmine, galantamine) improve cognition and function. Moderate to severe disease: memantine added to or replacing the cholinesterase inhibitor. Disease-modifying anti-amyloid antibodies (lecanemab and donanemab) are now available for early Alzheimer disease in selected patients with biomarker confirmation, removing amyloid plaques and slowing decline by around thirty percent over eighteen months. Behavioural symptoms (agitation, depression, sleep problems) are managed with structured non-drug strategies first, then carefully chosen medications. Centres at All India Institute of Medical Sciences, National Institute of Mental Health and Neurosciences, Fortis Memorial Research Institute, Medanta, Apollo, and BLK-Max offer dedicated memory clinics with amyloid imaging and anti-amyloid therapy programmes.

Recovery, Success Rates, and Follow-Up

Cholinesterase inhibitors slow decline modestly over twelve to eighteen months in most patients. Anti-amyloid antibodies slow clinical progression by around twenty-five to thirty-five percent over eighteen months in patients with mild cognitive impairment or mild dementia confirmed by biomarkers. Magnetic resonance imaging is repeated during anti-amyloid therapy to watch for amyloid-related imaging abnormalities. Follow-up runs every three to six months.

How to Choose the Right Alzheimer Disease Doctor

Pick a neurologist or geriatrician running a structured memory clinic with cognitive testing, magnetic resonance imaging access, biomarker confirmation, and the experience to deliver anti-amyloid infusions safely. Ask about amyloid-related imaging abnormality monitoring protocols, caregiver support pathways, and capacity assessment. A clinic that prescribes donepezil without staging or biomarker workup is the wrong fit for modern care.

International Patient Support

Alzheimer care in India, including biomarker testing, magnetic resonance imaging, and anti-amyloid therapy, costs far less than in the United Kingdom or United Arab Emirates with the same drugs and imaging quality. Cancer Rounds arranges the medical visa invitation letter, accommodation, caregiver support, multilingual support in eleven plus languages, and a single case manager throughout. Patients travel from Nigeria, Bangladesh, Kenya, Ethiopia, Iraq, Oman, and the United Arab Emirates for biomarker confirmation and anti-amyloid therapy.

Frequently Asked Questions

Is Alzheimer disease the same as dementia?

No. Dementia is a syndrome of memory and thinking problems severe enough to affect daily life. Alzheimer disease is the most common cause of dementia. Other causes include vascular dementia, Lewy body dementia, and frontotemporal dementia, each treated differently.

Do anti-amyloid drugs cure Alzheimer disease?

No. Lecanemab and donanemab slow decline by around thirty percent over eighteen months in early Alzheimer disease confirmed by biomarkers. They do not reverse damage already done. Eligibility, infusion logistics, and monitoring are strict.

Should we tell the patient the diagnosis?

Yes, in most cases, while capacity is intact. It allows planning, advance directives, and informed decisions about care and finances. The discussion is done sensitively and supported with written information and follow-up.

What are amyloid-related imaging abnormalities?

Brain swelling or small bleeds seen on magnetic resonance imaging during anti-amyloid therapy. Most are asymptomatic and detected on routine monitoring scans. Carriers of the apolipoprotein E epsilon four allele are at higher risk, which is why genetic testing is done before starting therapy.

Will the patient need a care home?

Many patients can stay at home with structured support, daycare programmes, and family caregivers. Care home placement becomes necessary when behavioural symptoms, falls, or wandering make home care unsafe. Planning early helps.

Can lifestyle changes slow progression?

Yes. Blood pressure control, diabetes control, hearing aid use, social engagement, exercise, Mediterranean-style diet, and structured cognitive activity all show modest benefit. They work alongside medication, not instead of it.